SpecialtiesQuestion

Would you add pertuzumab to adjuvant therapy for a premenopausal female with HR+, HER2+ IDC with N1mic disease?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?

In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?

What are your top takeaways in Breast Cancer from ESMO 2025?

When making treatment decisions, how do you deal with conflicting results on HER2 measurement via IHC, FISH, and Oncotype Dx HER2 expression levels?

In which scenarios would you consider adjuvant CDK4/6 inhibitor use if there is only one ipsilateral axillary lymph node positive for microscopic disease?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.